{"id":"losartan-and-hctz","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Dizziness"},{"rate":"3-5","effect":"Fatigue"},{"rate":"1-3","effect":"Hyperkalemia (losartan component)"},{"rate":"5-10","effect":"Hypokalemia (HCTZ component)"},{"rate":"2-5","effect":"Hyperglycemia"},{"rate":"1-3","effect":"Hyperuricemia"},{"rate":"rare","effect":"Cough"}]},"_chembl":{"chemblId":"CHEMBL382821","moleculeType":"Small molecule","molecularWeight":"467.92"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Losartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors on vascular smooth muscle, causing vasodilation and reduced peripheral resistance. Hydrochlorothiazide (HCTZ) is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, promoting urinary sodium and water loss and decreasing circulating blood volume. The combination provides complementary antihypertensive effects through different mechanisms.","oneSentence":"Losartan blocks angiotensin II receptors to relax blood vessels, while HCTZ increases sodium and water excretion to reduce blood volume, together lowering blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:53:07.020Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Reduction of cardiovascular risk in hypertensive patients"}]},"trialDetails":[{"nctId":"NCT03295734","phase":"PHASE2","title":"ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2018-05-29","conditions":"Hypertension, Aging, Sedentary Lifestyle","enrollment":223},{"nctId":"NCT04158154","phase":"NA","title":"Transforming Hypertension Treatment in Nigeria Using a Type II Hybrid, Interrupted Time Series Design","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2020-02-01","conditions":"Hypertension","enrollment":21922},{"nctId":"NCT03946514","phase":"PHASE4","title":"Efficacy and Safety of a Single-pill Fixed Combination of Sufficient Losartan/Hydrochlorothiazide in Chinese Hypertensive Patients","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2018-09-01","conditions":"Hypertension","enrollment":180},{"nctId":"NCT04927299","phase":"PHASE3","title":"Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2022-06-30","conditions":"Essential Arterial Hypertension","enrollment":163},{"nctId":"NCT00398541","phase":"PHASE3","title":"Evaluation of the Antihypertensive Effect of Hyzaar(R) and Cognitive Function of Hypertensive Patients (0954A-322)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-03-01","conditions":"Hypertension","enrollment":41},{"nctId":"NCT00307060","phase":"PHASE3","title":"MK0954A-264 Filter Study (0954A-264)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-12-01","conditions":"Mild to Severe Hypertension","enrollment":274},{"nctId":"NCT00480805","phase":"PHASE3","title":"HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-08-08","conditions":"Type 2 Diabetes Mellitus, Hypertension","enrollment":312},{"nctId":"NCT00400218","phase":"PHASE3","title":"Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-09-01","conditions":"Hypertension","enrollment":62},{"nctId":"NCT00157963","phase":"PHASE4","title":"Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-02-05","conditions":"Essential Hypertension","enrollment":174},{"nctId":"NCT00449111","phase":"PHASE3","title":"An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension (0954A-325)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2006-03-13","conditions":"Hypertension","enrollment":11},{"nctId":"NCT00140959","phase":"PHASE4","title":"Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-02-01","conditions":"Hypertension","enrollment":120},{"nctId":"NCT06491940","phase":"NA","title":"Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan","status":"NOT_YET_RECRUITING","sponsor":"RESnTEC, Institute of Research","startDate":"2024-08-01","conditions":"Proteinuria","enrollment":234},{"nctId":"NCT00447603","phase":"PHASE3","title":"A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2007-05-24","conditions":"Hypertension","enrollment":40},{"nctId":"NCT06366386","phase":"","title":"Integrating Hypertension Management in DSD for HIV","status":"NOT_YET_RECRUITING","sponsor":"Infectious Diseases Research Collaboration, Uganda","startDate":"2024-06-15","conditions":"Hypertension, HIV","enrollment":1100},{"nctId":"NCT00496834","phase":"PHASE4","title":"LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-02-01","conditions":"Hypertension","enrollment":201},{"nctId":"NCT01431508","phase":"PHASE4","title":"A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-08-01","conditions":"Hypertension","enrollment":15},{"nctId":"NCT01307046","phase":"PHASE3","title":"MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-03-29","conditions":"Hypertension","enrollment":336},{"nctId":"NCT01307033","phase":"PHASE3","title":"A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-03-29","conditions":"Hypertension","enrollment":278},{"nctId":"NCT00546052","phase":"PHASE3","title":"A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-09-01","conditions":"Hypertension, Metabolic Disorder","enrollment":1738},{"nctId":"NCT00739674","phase":"PHASE3","title":"SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-02-01","conditions":"Hypertension","enrollment":992},{"nctId":"NCT03461003","phase":"PHASE4","title":"N-of-1 Trials In Children With Hypertension","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2018-04-02","conditions":"Pediatric Hypertension","enrollment":49},{"nctId":"NCT01620788","phase":"PHASE3","title":"Comparison of Losartan Associated With Indapamide Versus Hyzaar® in the Hypertension Treatment","status":"SUSPENDED","sponsor":"EMS","startDate":"2019-11-27","conditions":"Hypertension","enrollment":636},{"nctId":"NCT00092209","phase":"PHASE3","title":"Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-04","conditions":"Hypertension","enrollment":840},{"nctId":"NCT00953680","phase":"PHASE1","title":"Bioequivalence of Losartan and Hydrochlorothiazide (HCTZ) Combination Tablet and Coadministration of Its Components (0954A-306)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-04","conditions":"Hypertension","enrollment":77},{"nctId":"NCT00289887","phase":"PHASE3","title":"Obese Hypertension Study (0954-315)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-02","conditions":"Hypertension","enrollment":261},{"nctId":"NCT02278471","phase":"PHASE2","title":"The SCCS Polypill Pilot Trial","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2015-12","conditions":"Hypertension, Hyperlipidemia","enrollment":303},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT03978884","phase":"PHASE4","title":"Phase 4 Study of the Efficacy of Losartan Based Therapy in Hypertensives With and Without Diabetes","status":"WITHDRAWN","sponsor":"The University of The West Indies","startDate":"2019-06-01","conditions":"Diabetes Mellitus, Hypertension","enrollment":""},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT00673790","phase":"PHASE4","title":"The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2008-05-15","conditions":"Hypertension","enrollment":537},{"nctId":"NCT02744456","phase":"EARLY_PHASE1","title":"N-of-1 Trials for Blood Pressure Medications in Adults","status":"COMPLETED","sponsor":"Columbia University","startDate":"2014-08-01","conditions":"Hypertension, High Blood Pressure","enrollment":10},{"nctId":"NCT01302691","phase":"PHASE3","title":"MK-0954E Study in Participants With Hypertension (MK-0954E-357)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-01","conditions":"Hypertension","enrollment":327},{"nctId":"NCT03578042","phase":"PHASE4","title":"Fixed-Free HTN Trial","status":"UNKNOWN","sponsor":"Hotel Dieu de France Hospital","startDate":"2017-04-01","conditions":"Hypertension","enrollment":100},{"nctId":"NCT03147092","phase":"EARLY_PHASE1","title":"Matão Controlling Hypertension (MatCH Study): Rationale and Design","status":"UNKNOWN","sponsor":"Centro Neurológico de Pesquisa e Reabiitação, Brazil","startDate":"2018-02-01","conditions":"Hypertension, Blood Pressure","enrollment":15000},{"nctId":"NCT01218724","phase":"PHASE1","title":"Bioequivalence Study of Losartan Potassium and Hydrochlorothiazide (100 mg / 25 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Hyzaar® (100 mg / 25 mg Tablet) [Reference Formulation, Merck & Co., Inc., USA] in Healthy Human Volunteers Under Fed Conditions","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT01218711","phase":"PHASE1","title":"Bioequivalence Study of Losartan Potassium and Hydrochlorothiazide (100 mg / 25 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Hyzaar® (100 mg / 25 mg Tablet) [Reference Formulation, Merck & Co., Inc., USA] in Healthy Human Volunteers Under Fasting Conditions.","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT00223717","phase":"PHASE1","title":"Treatment of Supine Hypertension in Autonomic Failure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2001-01","conditions":"Hypertension","enrollment":152},{"nctId":"NCT01891513","phase":"","title":"ACE Inhibitors Combined With Exercise for Seniors - Pilot Study","status":"COMPLETED","sponsor":"University of Florida","startDate":"2014-01","conditions":"Hypertension, Aging","enrollment":104},{"nctId":"NCT01964079","phase":"PHASE4","title":"Comparision of Blood Pressure Variability Between Amlodipine and Losartan","status":"COMPLETED","sponsor":"Wonju Severance Christian Hospital","startDate":"2013-04","conditions":"Hypertension","enrollment":144},{"nctId":"NCT00354991","phase":"PHASE3","title":"Hyzaar Asia HEAALTH (0954A-950)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06-01","conditions":"Hypertension","enrollment":437},{"nctId":"NCT02294539","phase":"PHASE4","title":"Comparison of Effects Between Amlodipine and Hydrochlorothiazide in Combination With Losartan on 24-hr Central Blood Pressure in Hypertensive Patients","status":"COMPLETED","sponsor":"Chong-Jin Kim","startDate":"2014-08","conditions":"Hypertension","enrollment":231},{"nctId":"NCT02521246","phase":"PHASE3","title":"Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control","status":"WITHDRAWN","sponsor":"EMS","startDate":"2016-11","conditions":"Essential Arterial Hypertension","enrollment":""},{"nctId":"NCT02521233","phase":"PHASE3","title":"Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control","status":"WITHDRAWN","sponsor":"EMS","startDate":"2016-11","conditions":"Essential Arterial Hypertension","enrollment":""},{"nctId":"NCT02900729","phase":"PHASE3","title":"Randomized Controlled Trial of Renal Denervation for Resistant Hypertension","status":"UNKNOWN","sponsor":"Shanghai WiseGain Medical Devices Co., Ltd.","startDate":"2016-10","conditions":"Hypertension","enrollment":254},{"nctId":"NCT00886600","phase":"PHASE3","title":"A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1991-05","conditions":"Hypertension","enrollment":122},{"nctId":"NCT00492128","phase":"PHASE4","title":"Kanagawa Combination Anti-hypertensive Therapy (K-CAT)","status":"COMPLETED","sponsor":"Yokohama City University Medical Center","startDate":"2007-09","conditions":"Hypertension","enrollment":196},{"nctId":"NCT01176032","phase":"PHASE4","title":"ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-06","conditions":"Hypertension, Left Ventricle Hypertrophy","enrollment":74},{"nctId":"NCT02183701","phase":"PHASE3","title":"Telmisartan Compared to Losartan + Hydrochlorothiazide in Patients With Mild-to-moderate Essential Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-04","conditions":"Hypertension","enrollment":715},{"nctId":"NCT02172586","phase":"PHASE4","title":"Telmisartan With or Without Hydrochlorothiazide (HCTZ) Compared With Losartan With or Without HCTZ in Mild to Moderate Hypertensive Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-01","conditions":"Hypertension","enrollment":363},{"nctId":"NCT00133185","phase":"PHASE3","title":"A Randomized, Double-blind, Parallel-group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg (Micardis Plus) in Comparison With Losartan 50mg Plus Hydrochlorothiazide 12.5mg in Taiwanese Patients With Mild to Moderate Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2004-03","conditions":"Hypertension","enrollment":31},{"nctId":"NCT01713647","phase":"PHASE1","title":"Bioequivalence Study of Amlodipine / Losartan/ Hydrochlorothiazide of PHARMALINE, Lebanon Under Fastion Conditions","status":"COMPLETED","sponsor":"Pharmaceutical Research Unit, Jordan","startDate":"2012-10","conditions":"Fasting","enrollment":39},{"nctId":"NCT00994617","phase":"PHASE4","title":"Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension","status":"UNKNOWN","sponsor":"University of Cambridge","startDate":"2010-01","conditions":"Hypertension, Resistant to Conventional Therapy, Essential Hypertension","enrollment":600},{"nctId":"NCT01087749","phase":"PHASE1","title":"Pharmacokinetic Study in Patients With Chronic Kidney Disease and Healthy Volunteers","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2010-03","conditions":"Kidney Disease","enrollment":24},{"nctId":"NCT01858623","phase":"NA","title":"Pharmacokinetic Interactions of Losartan and Hydrochlorothiazide","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2013-02","conditions":"Healthy Normotensive Participants","enrollment":18},{"nctId":"NCT01828359","phase":"PHASE4","title":"The Efficacy and Safety Study of Anti-hypertension Combination Drug in Patients Uncontrolled With Monotherapy.","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2010-08","conditions":"Hypertension","enrollment":199},{"nctId":"NCT01198496","phase":"PHASE4","title":"Recurrent Stroke Prevention Clinical Outcome Study","status":"UNKNOWN","sponsor":"Biomedis International Ltd.","startDate":"2010-10","conditions":"Hypertension, Stroke, Blood Pressure","enrollment":5000},{"nctId":"NCT00795847","phase":"PHASE4","title":"Morning Hypertension and Preminent Therapy Study","status":"COMPLETED","sponsor":"Kurume University","startDate":"2008-11","conditions":"Hypertension","enrollment":216},{"nctId":"NCT00446563","phase":"PHASE3","title":"Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-03","conditions":"Hypertension; Hypertrophy, Left Ventricular","enrollment":90},{"nctId":"NCT01271374","phase":"PHASE4","title":"Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome","status":"UNKNOWN","sponsor":"InVasc Therapeutics, Inc.","startDate":"2010-04","conditions":"Hypertension","enrollment":80},{"nctId":"NCT01198249","phase":"PHASE1","title":"Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide in Subjects With (Pre)Hypertension","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2010-09","conditions":"Essential Hypertension","enrollment":23},{"nctId":"NCT00670787","phase":"PHASE3","title":"Combination Pill of Losartan Potassium and Hydrochlorothiazide for Improvement of Medication Compliance Trial","status":"COMPLETED","sponsor":"Kyushu University","startDate":"2008-06","conditions":"Hypertension","enrollment":207},{"nctId":"NCT00931710","phase":"PHASE4","title":"Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-07","conditions":"Stage 2 Systolic Hypertension","enrollment":488},{"nctId":"NCT01127217","phase":"PHASE3","title":"Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Stage 2 Hypertension","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2009-05","conditions":"Hypertension","enrollment":149},{"nctId":"NCT00617877","phase":"NA","title":"Antihypertensive Response to Losartan and Genetic Polymorphisms","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Hypertension","enrollment":800},{"nctId":"NCT00369538","phase":"PHASE4","title":"Specific Blockage of Angiotensine 2 and Podocyturia in Glomerular Nephropathies With Hypertension and Proteinuria","status":"SUSPENDED","sponsor":"University Hospital, Strasbourg, France","startDate":"2006-08","conditions":"Proteinuria, Hypertension, End Stage Renal Disease","enrollment":20},{"nctId":"NCT00813722","phase":"PHASE4","title":"Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"1999-03","conditions":"Blood Pressure","enrollment":400},{"nctId":"NCT00751751","phase":"PHASE3","title":"Olmesartan Medoxomil Versus Losartan in Elderly and Very Elderly","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2003-06","conditions":"Essential Hypertension","enrollment":441},{"nctId":"NCT00234858","phase":"PHASE4","title":"Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR)","status":"COMPLETED","sponsor":"Abbott","startDate":"2004-03","conditions":"Hypertension, Metabolic Syndrome","enrollment":280}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"NAUSEA"},{"count":1,"reaction":"BLOOD GLUCOSE INCREASED"},{"count":1,"reaction":"BLOOD TRIGLYCERIDES INCREASED"},{"count":1,"reaction":"BRONCHITIS"},{"count":1,"reaction":"CHEST PAIN"},{"count":1,"reaction":"DIZZINESS"},{"count":1,"reaction":"DRUG DOSE OMISSION"},{"count":1,"reaction":"DRUG INEFFECTIVE"},{"count":1,"reaction":"DYSPNOEA"},{"count":1,"reaction":"FEELING ABNORMAL"}],"_approvalHistory":[],"publicationCount":168,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Hyzaar","Azor","Hydrochlorothiazide","Spironolactone"],"phase":"marketed","status":"active","brandName":"losartan and HCTZ","genericName":"losartan and HCTZ","companyName":"InVasc Therapeutics, Inc.","companyId":"invasc-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Losartan blocks angiotensin II receptors to relax blood vessels, while HCTZ increases sodium and water excretion to reduce blood volume, together lowering blood pressure. Used for Hypertension, Reduction of cardiovascular risk in hypertensive patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}